BAN2401 – pharmaceutical daily

Eisai, Biogen kick-off phase 3 testing early Alzheimer’s disease antibody, amid dropping aducanunab trial. Eisai’s US company presents AD pipeline

March 22, 2019March 22, 2019 Dino Mustafić 0 Comments BAN2401, Biogen, Eisai

Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.